Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.

[1]  R. Califf,et al.  Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention , 1995 .

[2]  R. Califf,et al.  Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial) , 1995 .

[3]  R. Califf,et al.  Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months , 1994, The Lancet.

[4]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[5]  C. Gaos,et al.  Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. , 1994, Journal of the American College of Cardiology.

[6]  R. Califf,et al.  Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein llb/llla in patients undergoing elective coronary angioplasty , 1993, Coronary artery disease.

[7]  D. Phillips,et al.  Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. , 1993, The Journal of biological chemistry.

[8]  E. Topol,et al.  Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. , 1992, Journal of the American College of Cardiology.

[9]  E. Topol,et al.  Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. , 1991, Journal of the American College of Cardiology.

[10]  L Schwartz,et al.  Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. , 1988, The New England journal of medicine.

[11]  L. Parise,et al.  The platelet membrane glycoprotein IIb-IIIa complex. , 1988, Blood.

[12]  Lynne H. Taylor,et al.  Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. , 1987, Circulation.

[13]  E. Ruoslahti,et al.  Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets. , 1987, Blood.

[14]  E F Cook,et al.  Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. , 1987, The American journal of medicine.

[15]  V. Fuster,et al.  Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. , 1985, Circulation research.